PFE

Has JNJ Finally Moved Past Its Quality-Control Woes?

Johnson & Johnson is throwing off billions of dollars to settle quality-control cases, but has Alex Gorsky ensured the worst is over for JNJ? More 

New Guidelines: Doctors to Push Use of Cholesterol Drugs

New heart disease prevention guidelines will have doctors recommending cholesterol drugs to double the Americans than what the current guidelines do. More 

These 48 Blue Chips Are On the Move

It's time to review or gradings for 48 Blue Chip stocks in our portfolio More 

Twitter IPO the Clear Headliner in a Big Week of Deals

The Twitter IPO will get the lion's share of headlines this week, but don't completely ignore the rest of this week's large slate of offerings. More 

Should I Buy JNJ Stock? 3 Pros, 3 Cons

Johnson & Johnson has had a killer year to so far, but the company faces some headwinds while JNJ stock looks a bit frothy. Should you buy? More 

Goldman Sachs Lists the Best Stocks for Dividends and Buybacks

Goldman notes in the report that S&P 500 companies that have strong buyback programs have in fact outperformed the market in the past 20 years More 

7 IPOs Look to Brave Rocky Markets

Despite rough terrain for the broader market, 7 companies are planning to go public this week. Here's an overview of each. More